Please ensure Javascript is enabled for purposes of website accessibility

Why Johnson & Johnson's Vaccine Data Is Actually Great News

By Morgan McSweeney - Updated Feb 8, 2021 at 10:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A few numbers from phase 3 trials stuck out for the wrong reasons. But looking closer, there's plenty to celebrate.

When set against efficacy data of the mRNA-based coronavirus vaccines developed by Moderna (MRNA -2.87%) and Pfizer (PFE 0.30%), which proved about 95% effective at keeping coronavirus infections at bay, Johnson & Johnson's (JNJ -0.60%) vaccine's results might not have inspired much optimism. The company's adenovirus vector vaccine was shown to be 66% effective at preventing moderate to severe COVID-19 in phase 3 trials.

But once we look deeper, the vaccine data is actually incredibly promising. Not to mention, there are plenty of logistical reasons why a one-dose vaccine could be a big winner. Johnson & Johnson has pledged not to profit off its vaccine during the pandemic, but once the public health crisis subsides, there could still be spoils left for the healthcare giant. Here's why that "66%" is not the red flag you might think it is.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$180.31 (-0.60%) $-1.09
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.57 (0.30%) $0.16
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$128.28 (-2.87%) $-3.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.